URL has been copied successfully!
Aurora Therapeutics, a startup focused on building personalized gene-editing drugs, has scrapped its lead program and slashed staff, just seven months after it launched, STAT has learned.
A company spokesperson declined to say how many employees were laid off, or whether any of the startup’s three-person leadership team would stay on. Aurora’s chief scientific officer left the company earlier this year.
The company appears to have been undercut by Beam Therapeutics, a larger and more established competitor. Just a month after Aurora launched, Beam announced it was already advancing its own set of custom gene editors for the exact same disease.
Please follow us:
